Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-392]
 ACTION: Notice of application.
 DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before November 17, 2017.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on August 9, 2017, Specgx LLC, 3600 North Second Street, Saint Louis, Missouri 63147 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: Controlled substance
Drug code
ScheduleGamma Hydroxybutyric Acid
2010
ITetrahydrocannabinols
7370
ICodeine-N-oxide
9053
IDihydromorphine
9145
IDifenoxin
9168
IMorphine-N-oxide
9307
INormorphine
9313
INorlevorphanol
9634
IAcetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)
9821
IButyryl Fentanyl
9822
IAmphetamine
1100
IIMethamphetamine
1105
IILisdexamfetamine
1205
IIMethylphenidate
1724
IINabilone
7379
II4-Anilino-N-phenethyl-4-piperidine (ANPP)
8333
IICodeine
9050
IIDihydrocodeine
9120
IIOxycodone
9143
IIHydromorphone
9150
IIDiphenoxylate
9170
IIEcgonine
9180
IIHydrocodone
9193
IILevorphanol
9220
IIMeperidine
9230
IIMethadone
9250
IIMethadone intermediate
9254
IIDextropropoxyphene, bulk (non-dosage forms)
9273
IIMorphine
9300
IIOripavine
9330
IIThebaine
9333
IIOpium tincture
9630
IIOpium, powdered
9639
IIOxymorphone
9652
IINoroxymorphone
9668
IIAlfentanil
9737
IIRemifentanil
9739
IISufentanil
9740
IITapentadol
9780
IIFentanyl
9801
II
 
 
 The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers. Dated: September 13, 2017 Demetra Ashley, Acting Assistant Administrator.


[FR Doc. 2017-19786 Filed 9-15-17; 8:45 am] BILLING CODE 4410-09-P